Scott BriggsPresident & CEO
Ed CincaChief Commercial Officer
Bethany SensenigChief Financial Officer
Joan GrayHead of Human Resources
Al MedwarSVP, Business & Corporate Development
Chhaya ShahChief Business Officer
Erika ToomanSVP / General Counsel
President & CEO
Scott Briggs is a senior pharmaceutical commercial executive with over 25 years’ experience in pharmaceutical marketing and sales, strategic planning, and business management. Scott most recently served as Chief Commercial Officer of Sebela Pharmaceuticals, a specialty pharmaceutical company with market leading brands in gastroenterology, women’s health, and dermatology. In this role he led all commercial functions, substantially growing sales of its branded products, planned, and successfully implemented multiple product launches and acted as a senior member of the Executive Leadership team. Prior to joining Sebela Pharmaceuticals, Mr. Briggs served as Vice President, Marketing and Sales at Noven Pharmaceuticals, where he led all commercial operations. Previously, he also served Noven in the roles of Vice President – women’s health sales, and Executive Director – marketing and managed markets. Prior to joining Noven, Scott was senior director of marketing for JDS Pharmaceuticals. He also held several leadership positions in management and marketing with Ortho-McNeil Pharmaceuticals (part of Johnson & Johnson). Mr. Briggs holds a BA in Business Administration from Villanova University.
Chief Commercial Officer
Ed is a recognized leader in the pharmaceutical industry, with diversified, progressive experience centered around small to multibillion-dollar product launches and commercialization. He brings with him 20 years of experience in pharma and biotech with strong emphasis on business strategy, innovation, execution, and transformation. Ed’s most recent role was as SVP/GM at Currax Pharmaceuticals, which is an industry leader in the treatment of obesity and smoking cessation. In this capacity, he led the relaunch of a mature brand leading to new market inroads, while simultaneously planning for the commercialization of a new product. Before that, he had a very successful career with Novo Nordisk, Inc. (NNI) serving as an Leadership team member and Vice President, Head of Cardiometabolic portfolio where he directed the launches of Ozempic, Rybelsus and Wegovy.
Chief Financial Officer
Bethany joined Radius in 2023, most recently serving as the CFO (and interim CEO) at publicly traded 9 Meters Bio, where she led $75M in debt and equity financing and worked with the Board to evaluate and execute strategic options. Prior to that, she was CFO and Head of US Operations at Minovia, a privately held biotech, leading investor relations, fundraising, business development, finance, and accounting functions. Additionally, Bethany spent 13 years at Biogen, where she led finance and commercial operations teams for specialty medicine and rare disease in the US, Asia-Pacific, Australia, Latin America, and Europe, directly accountable for a $1B commercial P&L, with 400+ commercial, finance and accounting people in 30+ countries. Early in her career, she held financial management and analyst roles at Merck & Co. Inc. and Nexus Technologies, Inc.
Bethany holds a Bachelor of Science in Accounting and Business Management from Montreat College, a Master of Business Administration from Western Carolina University and is a Certified Management Accountant.
Head of Human Resources
Joan serves as the company’s Head of Human Resources. She joined Radius in April 2021. She has over 25 years of human resources experience having worked in public and private organizations in the financial, manufacturing, healthcare, and clinical research industries. Prior to joining Radius, Joan was a Global HR Business Partner with PPD.
SVP, Business & Corporate Development
Al Medwar is an accomplished pharmaceutical executive with over 30 years of pharmaceutical industry experience. Prior to joining Radius, Al most recently served as Senior Vice President of Investor Relations and Corporate Communications and a member of the executive team at 9 Meters Biopharma, Inc., where he was responsible for investor and public relations and played a significant role in supporting strategic and business development efforts. He also served as Executive Vice President of Corporate & Commercial Development at Aruna Bio, Inc., a development stage biotechnology company, where he was responsible for investor relations strategy development and implementation and played a significant role in managing the fund-raising process as well as leading business development efforts. Al also previously served as Executive Vice President of Corporate and Business Development at BioDelivery Sciences where he played an integral role over twelve years in numerous successful business development and financing transactions through the transition of the company from a development stage to a commercial entity with multiple marketed products. Al received a BA from Cornell University and his MBA from Bentley University Graduate School of Business.
Chief Business Officer
Chhaya Shah has oversight of the company’s development and technical operations efforts for the abaloparatide and elacestrant assets and joined the company in July 2018. Prior to Radius, she was Senior Vice President at Synergy Pharmaceuticals as well as held significant leadership roles at Shire Pharmaceuticals, Wyeth Pharmaceuticals, and Abbott Laboratories.
Chhaya leads the company’s partnership and relationship with Menarini Group in support of the elacestrant molecule and program.
SVP / General Counsel
Erika Tooman, SVP / General Counsel, has more than two decades of legal pharmaceutical experience. An accomplished pharmaceutical executive and strategist, Erika oversees our corporate legal, intellectual property and compliance teams. She has wide-ranging experience in providing valuable legal perspective, establishing a clear vision, and implementing necessary strategy to achieve business goals. She previously served as General Counsel, Senior Vice President at Currax, where she continued to build her successful track record in corporate governance, risk management, intellectual property counseling and portfolio growth and management. She has also been a key contributor to the success of many licensing and M&A deals.
She is a recipient of the Healthcare Businesswomen’s Association Rising Star Award, is a registered patent attorney and is certified in healthcare compliance. Erika earned her JD from Brooklyn Law School, Master of Arts degree in Biotechnology from Columbia University, and Bachelor of Arts degree in Biology from Franklin & Marshall College. She is deeply involved in her local community and is a member of the Board of Directors for a local hospital in her community as well as a community college.